Assignment of liver allocation priority for hepatocellular carcinoma is predicated on accurate imaging staging. We analyzed radiographically defined stage (radiologic stage [RS]) at listing and most recent extension and pathologic stage (PS) data from 789 liver transplant recipients for whom no pretransplant ablative treatment was given. There were no predetermined imaging or pathological protocols in this retrospective analysis of wait list data. Seventy-two (9.1%), 690 (87.5%), and 27 (3.4%) were listed as stage 1, 2 and Ͼ2, respectively. Computed tomography (CT) scan alone (46.4%), magnetic resonance image scan alone (37.1%), ultrasound alone (1.3%), and multiple imaging studies (15.2%) were used with no difference in time to transplant for listing or most recent scan among the recipient groups. Overall accuracy (RS ϭ PS) was 44.1% and was not different if original listing RS or most recent RS was used for comparison with PS. No one type of imaging technique had superior accuracy (P ϭ 0.13); however, CT scan used alone or in combination compared to not being used at all, had higher odds of being accurate (odds ratio [OR]
See Editorial on Page 1445Liver transplantation for early-stage hepatocellular carcinoma (HCC) is more likely to provide a potential cure and improve survival than other less radical techniques. 1 These excellent results for liver transplantation depend on selection of patients with early, favorable-stage disease. Mazzafero et al. indicated that patients with single tumors less than 5 cm in size or 3 or fewer tumors no larger than 3 cm in size have excellent long-term recurrence-free survival. 2 This staging was based on histologic criteria evaluated in the explanted native liver retrospectively. Although this report summarized relatively few cases, many subsequent reports have confirmed that these so-called Milan criteria consistently identify HCC disease with favorable prognosis after liver transplantation. 3,4 How-